8-K: Pfizer Q3 2025: EPS Raised, Metsera Deal Progresses Amid Revenue Dip

Pfizer reported solid third-quarter 2025 financial results, raising and narrowing its full-year Adjusted diluted EPS guidance while reaffirming revenue guidance, and announced progress on key strategic initiatives including the Metsera acquisition and a landmark U.S. government agreement.

Summary

• Third-quarter 2025 revenues totaled $16.7 billion, a 6% decrease compared to the prior-year quarter, primarily due to a 7% operational decline.
• The non-COVID portfolio demonstrated strong commercial execution, achieving 4% operational revenue growth.
• Reported diluted EPS for Q3 2025 was $0.62, an 21% decrease from $0.78 in Q3 2024.
• Adjusted diluted EPS for Q3 2025 was $0.87, an 18% decrease from $1.06 in Q3 2024.
• Full-year 2025 revenue guidance was reaffirmed in the range of $61.0 billion to $64.0 billion.
• Full-year 2025 Adjusted diluted EPS guidance was raised and narrowed to a range of $3.00 to $3.15, up from the previous range of $2.90 to $3.10.
• The company is on track to deliver approximately $7.2 billion in overall anticipated net cost savings from previously announced cost improvement initiatives by the end of 2027.
• Pfizer reached a landmark agreement with the U.S. Government to ensure comparable drug prices and participate in a direct purchasing platform, TrumpRx.gov, offering significant discounts.
• Early FTC clearance was secured for the proposed Metsera acquisition, a clinical-stage biopharmaceutical company focused on obesity and cardiometabolic diseases, with an enterprise value of approximately $4.9 billion plus potential contingent value rights.
• Pfizer filed lawsuits against Metsera, Novo Nordisk A/S, and related parties concerning a competing proposal to acquire Metsera, alleging breach of contract, breach of fiduciary duty, tortious interference, and antitrust claims.
• The Phase 3 THRIVE-131 study for inclacumab, an investigational P-selectin inhibitor for sickle cell disease, did not meet its primary endpoint of significant reduction in vaso-occlusive crises.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While overall revenues declined due to COVID-19 products and a pipeline asset failed, the company raised its EPS guidance, showed strong growth in its non-COVID portfolio, and made significant strategic moves in high-growth areas like obesity, backed by a landmark U.S. government agreement. The ongoing litigation for the Metsera acquisition introduces some uncertainty.

Positives

• Raised and narrowed full-year 2025 Adjusted diluted EPS guidance to $3.00-$3.15, reflecting confidence in business performance and cost improvement initiatives.
• Non-COVID portfolio achieved 4% operational revenue growth in Q3 2025, demonstrating strengthened commercial execution.
• Eliquis revenues increased 22% operationally, driven by higher global demand and favorable U.S. net price due to the IRA Medicare Part D Redesign.
• Vyndaqel family revenues grew 7% operationally, supported by strong demand and increased patient diagnosis in key markets.
• Nurtec ODT/Vydura revenues rose 22% operationally, fueled by strong U.S. demand and recent international launches.
• Positive Phase 2 four-year data for Braftovi + Mektovi in metastatic non-small cell lung cancer, showing promising median overall survival rates.
• Positive Phase 3 results for Padcev in combination with pembrolizumab for muscle-invasive bladder cancer, demonstrating a 60% reduction in event-free survival risk and a 50% reduction in overall survival risk.
• Positive topline results from the Phase 3 HER2CLIMB-05 trial for Tukysa in first-line HER2+ metastatic breast cancer, meeting its primary endpoint of progression-free survival.
• Final OS results from the Phase 3 EMBARK study showed Xtandi plus leuprolide reduced the risk of death by 40.3% in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, making it the first and only AR inhibitor-based regimen to demonstrate an OS benefit in this indication.
• Secured early FTC clearance for the proposed Metsera acquisition, streamlining the regulatory approval process.
• Reached a landmark agreement with the U.S. Government to provide comparable drug prices and significant discounts on primary care and select specialty brands, along with a three-year tariff grace period for U.S. manufacturing investments.

Negatives

• Total revenues declined 6% (7% operationally) in Q3 2025 compared to the prior-year quarter, primarily driven by lower COVID-19 product revenues.
• Paxlovid revenues decreased 55% operationally due to lower COVID-19 infection rates, reduced international government purchases, and the non-recurrence of a $442 million U.S. government stockpile purchase in Q3 2024.
• Comirnaty revenues declined 20% operationally, mainly due to a narrower recommendation for vaccination in the U.S. and delayed approval of the new variant vaccine.
• Reported diluted EPS decreased 21% in Q3 2025, and Adjusted diluted EPS decreased 18% compared to Q3 2024.
• Acquired In-Process R&D Expenses increased significantly by $1.4 billion in Q3 2025, primarily due to a $1.35 billion charge for an in-licensing agreement with 3SBio, Inc., which had an unfavorable impact of approximately $0.20 on EPS.
• The Phase 3 THRIVE-131 study evaluating inclacumab for sickle cell disease did not meet its primary endpoint, leading to an intangible asset impairment charge of $260 million.
• Abrysvo revenues decreased 22% operationally in Q3 2025.
• Octagam revenues decreased 49% operationally in Q3 2025.

Risks

• The outcome of research and development activities, including the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for trials, regulatory submission dates, and/or regulatory approval and/or launch dates.
• The possibility of unfavorable pre-clinical and clinical trial results, including new data and further analyses of existing data, and risks associated with preliminary, early stage or interim data.
• Regulatory decisions impacting labeling, approval or authorization, including the scope of indicated patient populations, product dosage, manufacturing processes, safety, and potential product impurities.
• Uncertainties regarding the ability to obtain or maintain, and the scope of, recommendations by technical or advisory committees, and the timing of, and ability to obtain, pricing approvals and product launches.
• Claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including from post-approval clinical trials, pharmacovigilance, or Risk Evaluation and Mitigation Strategies.
• Risks and uncertainties related to the proposed acquisition of Metsera and the impact of Novo Nordisk's competing proposal, including the ability to satisfy closing conditions, realize anticipated benefits, and challenges integrating businesses and operations.
• Competition from new product entrants, in-line branded products, generic products, private label products, biosimilars, and product candidates.
• Difficulties or delays in manufacturing, sales or marketing, and supply disruptions, shortages or stock-outs.
• Risks and uncertainties related to Comirnaty and Paxlovid, including reduced demand due to endemic and seasonal market conditions, lower infection rates, excess inventory, and uncertainties related to variant-adapted vaccines and recommendations.
• Trends toward managed care and healthcare cost containment, and the ability to obtain or maintain timely or adequate pricing or favorable formulary placement for products.
• Interest rate and foreign currency exchange rate fluctuations, including the impact of global trade tensions, currency devaluations, and monetary policy actions.
• The exposure of operations globally to possible capital and exchange controls, economic conditions, expropriation, sanctions, tariffs, and/or other restrictive government actions.
• The risk and impact of tariffs on the business, including restrictions on trade, effective date and duration, and potential retaliatory tariffs.
• The impact of any U.S. healthcare reform or legislation, including the Inflation Reduction Act of 2022 (IRA) and the IRA Medicare Part D Redesign, or changes in tax treatment of employer-sponsored health insurance.
• Risks and uncertainties related to the impact of Pfizer's voluntary agreement with the U.S. Government, including entering into definitive agreements and the initiation of new tariffs not subject to Pfizer's grace period.
• Governmental laws, regulations, and policies affecting operations, including the One Big Beautiful Bill Act, global minimum taxation requirements, and potential changes to existing tax laws or tariffs.
• The risk that currently pending or future patent applications may not be granted, or patent-term extensions may not be granted, and risks to products, patents, and other intellectual property from claims of invalidity or infringement.
• Any significant breakdown or interruption of information technology systems and infrastructure, and business disruption, theft of confidential information, or security threats resulting from cyber-attacks, including those using adversarial artificial intelligence techniques.

Future Outlook

Pfizer reaffirms its full-year 2025 revenue guidance and has raised and narrowed its Adjusted diluted EPS guidance, reflecting confidence in its business performance and ongoing cost improvement initiatives. The company is on track to deliver approximately $7.2 billion in net cost savings by the end of 2027. While no share repurchases are anticipated in 2025, Pfizer expects to continue de-leveraging in a prudent manner to maintain flexibility for potential value-creating business development and future capital returns to shareholders. The company's guidance absorbs the impact of currently imposed tariffs from China, Canada, and Mexico.

Management Comments

• Dr. Albert Bourla, Chairman and CEO: "I am proud of Pfizer's leadership as the first in our industry to reach an agreement with the U.S. Government, which we believe provides greater clarity for our business. Additionally, our recent strategic actions have strengthened opportunities to advance innovation that could address significant medical needs in high growth markets, helping us deliver value for patients and shareholders."
• David Denton, CFO and EVP: "Our third-quarter performance demonstrates our continued focus on execution and financial discipline. We raised and narrowed our full-year 2025 Adjusted diluted EPS guidance, underscoring confidence in our ability to deliver strong results for our shareholders."

Industry Context

The pharmaceutical industry is navigating evolving market dynamics, including the transition of COVID-19 product demand from pandemic to endemic/seasonal patterns, which significantly impacted Pfizer's Q3 revenues. The company's strategic move to acquire Metsera highlights a strong focus on high-growth markets like obesity and cardiometabolic diseases, signaling an intent to compete meaningfully in this rapidly expanding therapeutic area. Furthermore, the landmark agreement with the U.S. Government reflects increasing pressure on drug pricing and a trend towards greater transparency and affordability, potentially setting a precedent for other pharmaceutical companies.

Comparison to Industry Standards

• Pfizer's acquisition of Metsera positions it to compete in the rapidly growing obesity and cardiometabolic disease market, where companies like Novo Nordisk A/S are already established leaders with products like Ozempic and Wegovy. Novo Nordisk's competing proposal for Metsera underscores the high value and competitive nature of this therapeutic area.
• The U.S. government agreement for comparable drug prices and the TrumpRx.gov platform could set a new benchmark for pharmaceutical companies operating in the U.S., potentially influencing pricing strategies across the industry.

Legal Proceedings

• Pfizer filed lawsuits against Metsera, Novo Nordisk A/S, and several related parties and individuals in the Delaware Court of Chancery and the U.S. District Court of the District of Delaware.
• The lawsuits relate to a competing proposal to acquire Metsera made by Novo Nordisk on October 25, 2025.
• Claims include breach of contract, breach of fiduciary duty, tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera, as well as various antitrust-related claims.
• Pfizer is requesting the Delaware Court of Chancery issue a temporary restraining order to block Metsera from terminating the merger agreement and seeks all appropriate remedies to ensure the terms of the merger agreement are fully enforced.

Stakeholder Impact

• Shareholders: Potential for increased value from raised EPS guidance, strategic acquisitions, and dividends, but also exposure to risks from litigation and declining COVID-19 product revenues.
• Patients: Potential for lower drug costs through the U.S. government agreement and access to new treatments from the pipeline, particularly in oncology and obesity.
• U.S. Government/Taxpayers: Benefit from the agreement designed to ensure comparable drug prices and significant discounts on certain Pfizer products.
• Employees: Impacted by ongoing cost realignment and R&D re-organization initiatives, which include employee termination costs.
• Metsera: Subject of a pending acquisition and related legal disputes, affecting its shareholders and future direction.
• Novo Nordisk: Directly involved in a competitive acquisition bid and subsequent lawsuits, potentially impacting its strategic positioning in the obesity market.

Next Steps

• Continue to execute on cost improvement initiatives to achieve approximately $7.2 billion in net cost savings by the end of 2027.
• Monitor and resolve the lawsuits filed against Metsera and Novo Nordisk A/S regarding the competing acquisition proposal for Metsera.
• Integrate Metsera post-acquisition to advance innovation in obesity and cardiometabolic diseases.
• Continue to de-lever in a prudent manner to maintain a balanced capital allocation strategy.
• Maintain flexibility to deploy capital towards potential value-creating business development transactions and potential share repurchases.
• Further invest in manufacturing in the United States as part of the agreement with the U.S. Government.

Key Dates

Recommendation

While Pfizer demonstrated resilience by raising its full-year Adjusted diluted EPS guidance and achieving strong operational growth in its non-COVID portfolio, the overall revenue decline driven by COVID-19 products and a pipeline setback (inclacumab) present notable headwinds. The strategic acquisition of Metsera and the landmark U.S. government pricing agreement are positive long-term catalysts, but the ongoing litigation surrounding the Metsera deal introduces near-term uncertainty and potential execution risks. A 'hold' recommendation is appropriate as investors should monitor the successful integration of Metsera, the resolution of legal disputes, and the sustained performance of the non-COVID product portfolio before making further investment decisions.

Keywords

Pfizer, PFE, Q3 2025, Earnings, Financial Results, Guidance, Metsera, Acquisition, Obesity, Cardiometabolic, COVID-19, Paxlovid, Comirnaty, Eliquis, Vyndaqel, Nurtec ODT, Oncology, R&D, Cost Savings, U.S. Government Agreement, Litigation, Pharmaceuticals, Biopharma